Acadian Asset Management’s Entrada Therapeutics TRDA Stock Holding History

Acadian Asset Management’s Portfolio TRDA Stock Details TRDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.2M	Buy	333,169 +22,336	+7%	+$256K	0.01%	757
2025 Q4	$3.19M	Buy	310,833 +12,890	+4%	+$109K	0.01%	782
2025 Q3	$1.72M	Buy	297,943 +252,137	+550%	+$1.48M	﹤0.01%	929
2025 Q2	$306K	Buy	45,806 +24,665	+117%	+$198K	﹤0.01%	1230
2025 Q1	$190K	Sell	21,141 -30,350	-59%	-$378K	﹤0.01%	1266
2024 Q4	$890K	Sell	51,491 -14,032	-21%	-$254K	﹤0.01%	947
2024 Q3	$1.04M	Buy	65,523 +52,156	+390%	+$822K	﹤0.01%	902
2024 Q2	$190K	Buy	13,367 +7,682	+135%	+$109K	﹤0.01%	1434
2024 Q1	$79K	Buy	+5,685	New	+$80.4K	﹤0.01%	1321

Other funds holding TRDA

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management's TRDA Position: Q1 2026 in Review

Acadian Asset Management increased its Entrada Therapeutics (TRDA) stake by 7.2% in Q1 2026, buying an estimated $256K and bringing the position to 333,169 shares worth $4.2M. The position accounts for 0.01% of the portfolio, ranked #757.

Acadian Asset Management first reported a position in TRDA in Q1 2024 and has held it in 9 quarters since. 120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

Acadian Asset Management held 333,169 shares of Entrada Therapeutics worth $4.2M as of Q1 2026.
Acadian Asset Management bought 22,336 Entrada Therapeutics shares in Q1 2026, an estimated $256K.
Entrada Therapeutics made up 0.01% of Acadian Asset Management's portfolio in Q1 2026, its #757 holding.
Acadian Asset Management first reported a position in Entrada Therapeutics in Q1 2024 and has held it in 9 quarters since.
120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.